Market Place
Sourcing Support
Defender gets CRL from FDA on motion sickness nasal gel
31 Jan 2024 //
FIERCE PHARMA
Defender Receives CRL from the USFDA for its Intranasal Scopolamine
30 Jan 2024 //
GLOBENEWSWIRE
Defender Announces Collaboration with NASA on Two Phase 2 Clinical Trials
24 Oct 2023 //
GLOBENEWSWIRE
FDA Accepts Defender™ New Drug Application for Intranasal Scopolamine Gel
26 Sep 2023 //
GLOBENEWSWIRE
Defender Pharma Phase 3 Motion Sickness Trial Results Selected for Presentation
10 Aug 2023 //
GLOBENEWSWIRE
Defender Pharma Announces Exclusive License Agreement with the U.S. Army
31 Jul 2023 //
GLOBENEWSWIRE
Defender Announces Submission of NDA to FDA with Intranasal Scopolamine
26 Jul 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.